Advances in Molecular OncologyAdvances in Molecular OncologyУспехи молекулярной онкологии2313-805X2413-3787Publishing House ABV Press9810.17650/2313-805X-2017-4-3-21-26REVIEW ARTICLESОБЗОРНЫЕ СТАТЬИMetabolic aspects of adoptive immunotherapy of tumorsМетаболические аспекты адоптивной иммунотерапии опухолейKazanskiyD. B.КазанскийД. Б.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478.

115478 Москва, Каширское шоссе, 24.

kazansky1@yandex.ruSilaevaYu. Yu.СилаеваЮ. Ю.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478.

115478 Москва, Каширское шоссе, 24.

KalininaA. A.КалининаА. А.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478.

115478 Москва, Каширское шоссе, 24.

ZamkovaM. A.ЗамковаМ. А.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478.

115478 Москва, Каширское шоссе, 24.

KhromykhL. M.ХромыхЛ. М.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478.

115478 Москва, Каширское шоссе, 24.

PersiyantsevaN. A.ПерсиянцеваН. А.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478.

115478 Москва, Каширское шоссе, 24.

DzholokhavaL. Kh.ДжолохаваЛ. Х.
Russian Federation

24 Kashirskoe Shosse, Moscow 115478.

115478 Москва, Каширское шоссе, 24.

Research Institute of Carcinogenesis, N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia.НИИ канцерогенеза ФГБУ «Национальный медицинский исследовательский центр онкологии им. Н.Н. Блохина» Минздрава России.150920174321261610201716102017Copyright ©; 2017, Kazanskiy D.B., Silaeva Y.Y., Kalinina A.A., Zamkova M.A., Khromykh L.M., Persiyantseva N.A., Dzholokhava L.K.Copyright ©; 2017, Казанский Д.Б., Силаева Ю.Ю., Калинина А.А., Замкова М.А., Хромых Л.М., Персиянцева Н.А., Джолохава Л.Х.2017Kazanskiy D.B., Silaeva Y.Y., Kalinina A.A., Zamkova M.A., Khromykh L.M., Persiyantseva N.A., Dzholokhava L.K.Казанский Д.Б., Силаева Ю.Ю., Калинина А.А., Замкова М.А., Хромых Л.М., Персиянцева Н.А., Джолохава Л.Х.https://creativecommons.org/licenses/by/4.0https://umo.abvpress.ru/jour/article/view/98

In wide number of approaches to treatment of cancer immunotherapy plays special role. This approach exploits capabilities of immune system to support genetic constancy of different cells and tissues of the organism. Immunotherapy is designed to induce tumor cell destruction  by T-lymphocytes whose receptors can recognize peptides of mutant proteins complexed with the molecules of the major histocompatibility complex. In clinical practice T-lymphocytes can result in sustained and complete responses in patients whose cancers were resistant to available treatment options. Recent evidences suggest that efficiency of such therapy generally depends on metabolic properties of T-lymphocytes. A number of approaches allows modulate T-cell metabolism providing strategies to optimize activity of anti-tumor T-lymphocytes.

В широком ряду методов лечения онкологических заболеваний особое место принадлежит иммунотерапии – терапевтическому подходу, использующему возможности иммунной системы организма в поддержании генетического постоянства его клеток и тканей. Иммунотерапия нацелена на то, чтобы вызывать разрушение опухолевых клеток Т-лимфоцитами, чьи рецепторы способны распознать пептиды мутантных белков, связанные с молекулами главного комплекса гистосовместимости. В клинической практике Т-лимфоциты способны вызывать стойкое улучшение и даже полное излечение больных, опухоли которых устойчивы к другим доступным методам лечения. Ряд работ, появившихся в последние годы, указывают на то, что эффективность такой терапии в значительной степени зависит от процессов энергетического метаболизма Т-лимфоцитов. Существуют несколько подходов, способных модулировать метаболизм Т-лимфоцитов и достичь оптимального проявления их противоопухолевых свойств.

anti-tumor immunityglycolysisT-cell receptorimmunological memoryimmunometabolismпротивоопухолевый иммунитетгликолизТ-клеточный рецепториммунологическая памятьиммунометаболизм1. Mehlen P., Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer 2006;6(6):449–58.Mehlen P., Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer 2006;6(6):449–58.2. Cardoso F., Di L.A., Lohrisch C. et al. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol 2002;13(2):197–207.Cardoso F., Di L.A., Lohrisch C. et al. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann Oncol 2002;13(2):197–207.3. Spaans J.N., Goss G.D. Drug resistance to molecular targeted therapy and its consequences for treatment decisions in nonsmall-cell lung cancer. Front Oncol 2014;4:190.Spaans J.N., Goss G.D. Drug resistance to molecular targeted therapy and its consequences for treatment decisions in nonsmall-cell lung cancer. Front Oncol 2014;4:190.4. Rosenberg S.A., Restifo N.P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015;348(6230):62–8.Rosenberg S.A., Restifo N.P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 2015;348(6230):62–8.5. Robbins P.F. Morgan R.A., Feldman S.A. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011;29(7):917–24.Robbins P.F. Morgan R.A., Feldman S.A. et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol 2011;29(7):917–24.6. Sharma P., Allison J.P. The future of immune checkpoint therapy. Science 2015;348(6230):56–61.Sharma P., Allison J.P. The future of immune checkpoint therapy. Science 2015;348(6230):56–61.7. Kazansky D.B. Intrathymic selection: new insight into tumor immunology. Adv Exp Med Biol 2007;601:133–44.Kazansky D.B. Intrathymic selection: new insight into tumor immunology. Adv Exp Med Biol 2007;601:133–44.8. Казанский Д.Б. Т-лимфоциты в развитии хронического лимфолейкоза. Клиническая онкогематология 2012;5(2): 85–95. [Kazanskiy D.B. T-lymphocytes in the development of chronic lymphocytic leukemia. Klinicheskaya onkogematologiya = Clinical Oncohematology 2012;5(2):85–95. (In Russ.)].Казанский Д.Б. Т-лимфоциты в развитии хронического лимфолейкоза. Клиническая онкогематология 2012;5(2): 85–95. [Kazanskiy D.B. T-lymphocytes in the development of chronic lymphocytic leukemia. Klinicheskaya onkogematologiya = Clinical Oncohematology 2012;5(2):85–95. (In Russ.)].9. Казанский Д.Б., Силаева Ю.Ю., Калинина А.А. и др. Трансплантационный и специфический противоопухолевый иммунитет в ретроспективе: новые модели, основанные на трансгенезе цепей Т-клеточного рецептора. Успехи молекулярной онкологии 2016;3(1):14–27. [Kazanskiy D.B., Silaeva Yu.Yu., Kalini - na A.A. Transplantational and specific antitumor immunity in retrospective view: new models based on transgenesis of individual chains of T-cell receptor. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2016;3(1):14–27. (In Russ.)].Казанский Д.Б., Силаева Ю.Ю., Калинина А.А. и др. Трансплантационный и специфический противоопухолевый иммунитет в ретроспективе: новые модели, основанные на трансгенезе цепей Т-клеточного рецептора. Успехи молекулярной онкологии 2016;3(1):14–27. [Kazanskiy D.B., Silaeva Yu.Yu., Kalini - na A.A. Transplantational and specific antitumor immunity in retrospective view: new models based on transgenesis of individual chains of T-cell receptor. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2016;3(1):14–27. (In Russ.)].10. Kochenderfer J.N., Dudley M.E., Feldman S.A. et al. B-cell depletion and remissions of malignancy along with cytokineassociated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor- transduced T-cells. Blood 2012;119(12): 2709–20.Kochenderfer J.N., Dudley M.E., Feldman S.A. et al. B-cell depletion and remissions of malignancy along with cytokineassociated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor- transduced T-cells. Blood 2012;119(12): 2709–20.11. Grupp S.A., Kalos M., Barrett D. et al. Chimeric antigen receptor-modified Tcells for acute lymphoid leukemia. N Engl J Med 2013;368(16):1509–18.Grupp S.A., Kalos M., Barrett D. et al. Chimeric antigen receptor-modified Tcells for acute lymphoid leukemia. N Engl J Med 2013;368(16):1509–18.12. Rosenberg S.A., Yang J.C., Sherry R.M. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011;17(13):4550–7.Rosenberg S.A., Yang J.C., Sherry R.M. et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011;17(13):4550–7.13. Tran E., Robbins P.F., Lu Y.C. et al. T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med 2016;375(23):2255–62.Tran E., Robbins P.F., Lu Y.C. et al. T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med 2016;375(23):2255–62.14. Chang C.H., Pearce E.L. Emerging concepts of T-cell metabolism as a target of immunotherapy. Nat Immunol 2016;17(4):364–8.Chang C.H., Pearce E.L. Emerging concepts of T-cell metabolism as a target of immunotherapy. Nat Immunol 2016;17(4):364–8.15. Gattinoni L., Lugli E., Ji Y. et al. A human memory T-cell subset with stem cell-like properties. Nat Med 2011;17(10):1290–7.Gattinoni L., Lugli E., Ji Y. et al. A human memory T-cell subset with stem cell-like properties. Nat Med 2011;17(10):1290–7.16. Pearce E.L., Walsh M.C., Cejas P.J. et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009;460(7251):103–7.Pearce E.L., Walsh M.C., Cejas P.J. et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism. Nature 2009;460(7251):103–7.17. Michalek R.D., Gerriets V.A., Jacobs S.R. et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T-cell subsets. J Immunol 2011;186(6):3299–303.Michalek R.D., Gerriets V.A., Jacobs S.R. et al. Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T-cell subsets. J Immunol 2011;186(6):3299–303.18. Sukumar M., Gattinoni L. The short and sweet of T-cell therapy: restraining glycolysis enhances the formation of immunological memory and antitumor immune responses. Oncoimmunology 2016;3(1):e27573.Sukumar M., Gattinoni L. The short and sweet of T-cell therapy: restraining glycolysis enhances the formation of immunological memory and antitumor immune responses. Oncoimmunology 2016;3(1):e27573.19. Rosenberg S.A., Restifo N.P., Yang J.C. et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8(4):299–308.Rosenberg S.A., Restifo N.P., Yang J.C. et al. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8(4):299–308.20. Klebanoff C.A., Gattinoni L., TorabiParizi P. et al. Central memory self/tumorreactive CD8+ T-cells confer superior antitumor immunity compared with effector memory T-cells. Proc Natl Acad Sci U S A 2005;102(27):9571–76.Klebanoff C.A., Gattinoni L., TorabiParizi P. et al. Central memory self/tumorreactive CD8+ T-cells confer superior antitumor immunity compared with effector memory T-cells. Proc Natl Acad Sci U S A 2005;102(27):9571–76.21. Gattinoni L., Zhong X.S., Palmer D.C. et al. Wnt signaling arrests effector T-cell differentiation and generates CD8+ memory stem cells. Nat Med 2009;15(7): 808–13.Gattinoni L., Zhong X.S., Palmer D.C. et al. Wnt signaling arrests effector T-cell differentiation and generates CD8+ memory stem cells. Nat Med 2009;15(7): 808–13.22. Muranski P., Boni A., Antony P.A. et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008;112(2):362–73.Muranski P., Boni A., Antony P.A. et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008;112(2):362–73.23. Sukumar M., Liu J., Mehta G.U. et al. Mitochondrial membrane potential identifies cells with enhanced stemness for cellular therapy. Cell Metab 2016;23(1):63–76.Sukumar M., Liu J., Mehta G.U. et al. Mitochondrial membrane potential identifies cells with enhanced stemness for cellular therapy. Cell Metab 2016;23(1):63–76.24. Luckey C.J. Bhattacharya D., Goldrath A.W. et al. Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells. Proc Natl Acad Sci U S A 2006;103(9):3304–9.Luckey C.J. Bhattacharya D., Goldrath A.W. et al. Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells. Proc Natl Acad Sci U S A 2006;103(9):3304–9.25. Vannini N., Girotra M., Naveiras O. et al. Specification of haematopoietic stem cell fate via modulation of mitochondrial activity. Nat Commun 2016;7:13125.Vannini N., Girotra M., Naveiras O. et al. Specification of haematopoietic stem cell fate via modulation of mitochondrial activity. Nat Commun 2016;7:13125.26. Bertolo A., Capossela S., Fränkl G. et al. Oxidative status predicts quality in human mesenchymal stem cells. Stem Cell Res Ther 2017;8(1):3.Bertolo A., Capossela S., Fränkl G. et al. Oxidative status predicts quality in human mesenchymal stem cells. Stem Cell Res Ther 2017;8(1):3.27. Tothova Z., Kollipara R., Huntly B.J. et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 2007;128(2):325–39.Tothova Z., Kollipara R., Huntly B.J. et al. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 2007;128(2):325–39.28. Ito K., Hirao A., Arai F. et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature 2004;431(7011):997–1002.Ito K., Hirao A., Arai F. et al. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature 2004;431(7011):997–1002.29. Sena L.A., Li S., Jairaman A. et al. Mitochondria are required for antigen-specific T-cell activation through reactive oxygen species signaling. Immunity 2013;38(2):225–36.Sena L.A., Li S., Jairaman A. et al. Mitochondria are required for antigen-specific T-cell activation through reactive oxygen species signaling. Immunity 2013;38(2):225–36.30. Weinberg S.E., Sena L.A., Chandel N.S. et al. Mitochondria in the regulation of innate and adaptive immunity. Immunity 2015;42(3):406–17.Weinberg S.E., Sena L.A., Chandel N.S. et al. Mitochondria in the regulation of innate and adaptive immunity. Immunity 2015;42(3):406–17.31. Pollizzi K.N., Sun I.H., Patel C.H. et al. Asymmetric inheritance of mTORC1 kinase activity during division dictates CD8+ T-cell differentiation. Nat Immunol 2016;17(6):704–11.Pollizzi K.N., Sun I.H., Patel C.H. et al. Asymmetric inheritance of mTORC1 kinase activity during division dictates CD8+ T-cell differentiation. Nat Immunol 2016;17(6):704–11.32. Verbist K.C., Guy C.S., Milasta S. et al. Metabolic maintenance of cell asymmetry following division in activated T lymphocytes. Nature 2016;532(7599):389–93.Verbist K.C., Guy C.S., Milasta S. et al. Metabolic maintenance of cell asymmetry following division in activated T lymphocytes. Nature 2016;532(7599):389–93.33. Scholz G., Jandus C., Zhang L. et al. Modulation of mTOR signalling triggers the formation of stem cell-like memory T-cells. EBioMedicine 2016;4:50–61.Scholz G., Jandus C., Zhang L. et al. Modulation of mTOR signalling triggers the formation of stem cell-like memory T-cells. EBioMedicine 2016;4:50–61.34. Yang K., Neale G., Green D.R. et al. The tumor suppressor Tsc1 enforces quiescence of naive T-cells to promote immune homeostasis and function. Nat Immunol 2011;12(9):888–97.Yang K., Neale G., Green D.R. et al. The tumor suppressor Tsc1 enforces quiescence of naive T-cells to promote immune homeostasis and function. Nat Immunol 2011;12(9):888–97.35. Araki K., Turner A.P., Shaffer V.O. et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009;460(7251):108–12.Araki K., Turner A.P., Shaffer V.O. et al. mTOR regulates memory CD8 T-cell differentiation. Nature 2009;460(7251):108–12.36. Pollizzi K.N., Patel C.H., Sun I.H. et al. mTORC1 and mTORC2 selectively regulate CD8+ T-cell differentiation. J Clin Invest 2015;125(5):2090–108.Pollizzi K.N., Patel C.H., Sun I.H. et al. mTORC1 and mTORC2 selectively regulate CD8+ T-cell differentiation. J Clin Invest 2015;125(5):2090–108.37. Shrestha S., Yang K., Wei J. et al. Tsc1 promotes the differentiation of memory CD8+ T-cells via orchestrating the transcriptional and metabolic programs. Proc Natl Acad Sci U S A 2014;111(41): 14858–63.Shrestha S., Yang K., Wei J. et al. Tsc1 promotes the differentiation of memory CD8+ T-cells via orchestrating the transcriptional and metabolic programs. Proc Natl Acad Sci U S A 2014;111(41): 14858–63.38. Rao R.R., Li Q., Odunsi K., Shrikant P.A. The mTOR kinase determines effector versus memory CD8+ T-cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity 2010;32(1):67–78.Rao R.R., Li Q., Odunsi K., Shrikant P.A. The mTOR kinase determines effector versus memory CD8+ T-cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity 2010;32(1):67–78.39. O’Neill L.A., Kishton R.J., Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol 2016;16(9):553–65.O’Neill L.A., Kishton R.J., Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol 2016;16(9):553–65.40. Macintyre A.N., Gerriets V.A., Nichols A.G. et al. The glucose transporter Glut1 is selectively essential for CD4 T-cell activation and effector function. Cell Metab 2014;20(1):61–72.Macintyre A.N., Gerriets V.A., Nichols A.G. et al. The glucose transporter Glut1 is selectively essential for CD4 T-cell activation and effector function. Cell Metab 2014;20(1):61–72.41. Gerriets V.A., Kishton R.J., Nichols A.G. et al. Metabolic programming and PDHK1 control CD4+ T-cell subsets and inflammation. J Clin Invest 2015;125(1):194–207.Gerriets V.A., Kishton R.J., Nichols A.G. et al. Metabolic programming and PDHK1 control CD4+ T-cell subsets and inflammation. J Clin Invest 2015;125(1):194–207.42. Wang R., Dillon C.P., Shi L.Z. et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 2011;35(6):871–82.Wang R., Dillon C.P., Shi L.Z. et al. The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 2011;35(6):871–82.43. van der Windt G.J., Everts B., Chang C.H. et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T-cell memory development. Immunity 2012;36(1):68–78.van der Windt G.J., Everts B., Chang C.H. et al. Mitochondrial respiratory capacity is a critical regulator of CD8+ T-cell memory development. Immunity 2012;36(1):68–78.44. Sukumar M., Liu J., Ji Y. et al. Inhibiting glycolytic metabolism enhances CD8+ T-cell memory and antitumor function. J Clin Invest 2013;123(10):4479–88.Sukumar M., Liu J., Ji Y. et al. Inhibiting glycolytic metabolism enhances CD8+ T-cell memory and antitumor function. J Clin Invest 2013;123(10):4479–88.45. Patsoukis N., Bardhan K., Chatterjee P. et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun 2015;6:6692.Patsoukis N., Bardhan K., Chatterjee P. et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat Commun 2015;6:6692.46. Peng M., Yin N., Chhangawala S. et al. Aerobic glycolysis promotes T helper 1 cell differentiation through an epigenetic mechanism. Science 2016;354(6311):481–4.Peng M., Yin N., Chhangawala S. et al. Aerobic glycolysis promotes T helper 1 cell differentiation through an epigenetic mechanism. Science 2016;354(6311):481–4.47. Chang C.H., Curtis J.D., Maggi L.B. Jr et al. Posttranscriptional control of T-cell effector function by aerobic glycolysis. Cell 2013;153(6):1239–51.Chang C.H., Curtis J.D., Maggi L.B. Jr et al. Posttranscriptional control of T-cell effector function by aerobic glycolysis. Cell 2013;153(6):1239–51.48. Crompton J.G., Sukumar M., Roychoudhuri R. et al. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res 2015;75(2):296–305.Crompton J.G., Sukumar M., Roychoudhuri R. et al. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res 2015;75(2):296–305.49. Yang W., Bai Y., Xiong Y. et al. Potentiating the antitumour response of CD8+ T-cells by modulating cholesterol metabolism. Nature 2016;531(7596):651–5.Yang W., Bai Y., Xiong Y. et al. Potentiating the antitumour response of CD8+ T-cells by modulating cholesterol metabolism. Nature 2016;531(7596):651–5.50. Kawalekar O.U., O’Connor R.S., Fraietta J.A. et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T-cells. Immunity 2016;44(2):380–90.Kawalekar O.U., O’Connor R.S., Fraietta J.A. et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T-cells. Immunity 2016;44(2):380–90.51. Buck M.D., O’Sullivan D., Klein Geltink R.I. et al. Mitochondrial dynamics controls T-cell fate through metabolic programming. Cell 2016;166(1):63–76.Buck M.D., O’Sullivan D., Klein Geltink R.I. et al. Mitochondrial dynamics controls T-cell fate through metabolic programming. Cell 2016;166(1):63–76.52. Geiger R., Rieckmann J.C., Wolf T. et al. L-arginine modulates T-cell metabolism and enhances survival and anti-tumor activity. Cell 2016;167(3):829–42.Geiger R., Rieckmann J.C., Wolf T. et al. L-arginine modulates T-cell metabolism and enhances survival and anti-tumor activity. Cell 2016;167(3):829–42.53. Ho P.C., Bihuniak J.D., Macintyre A.N. et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T-cell responses. Cell 2015;162(6):1217–28.Ho P.C., Bihuniak J.D., Macintyre A.N. et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T-cell responses. Cell 2015;162(6):1217–28.54. Doedens A.L., Phan A.T., Stradner M.H. et al. Hypoxia-inducible factors enhance the effector responses of CD8+ T-cells to persistent antigen. Nat Immunol 2013;14(11):1173–82.Doedens A.L., Phan A.T., Stradner M.H. et al. Hypoxia-inducible factors enhance the effector responses of CD8+ T-cells to persistent antigen. Nat Immunol 2013;14(11):1173–82.55. Clever D., Roychoudhuri R., Constantinides M.G. et al. Oxygen sensing by T-cells establishes an immunologically tolerant metastatic niche. Cell 2016;166(5):1117–31.Clever D., Roychoudhuri R., Constantinides M.G. et al. Oxygen sensing by T-cells establishes an immunologically tolerant metastatic niche. Cell 2016;166(5):1117–31.56. Eil R., Vodnala S.K., Clever D. et al. Ionic immune suppression within the tumour microenvironment limits T-cell effector function. Nature 2016;537(7621):539–43.Eil R., Vodnala S.K., Clever D. et al. Ionic immune suppression within the tumour microenvironment limits T-cell effector function. Nature 2016;537(7621):539–43.57. Bengsch B., Johnson A.L., Kurachi M. et al. Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8+ T-cell exhaustion. Immunity 2016;45(2):358–73.Bengsch B., Johnson A.L., Kurachi M. et al. Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8+ T-cell exhaustion. Immunity 2016;45(2):358–73.58. Scharping N.E., Menk A.V., Moreci R.S. et al. The tumor microenvironment represses T-cell mitochondrial biogenesis to drive intratumoral T-cell metabolic insufficiency and dysfunction. Immunity 2016;45(2):374–88.Scharping N.E., Menk A.V., Moreci R.S. et al. The tumor microenvironment represses T-cell mitochondrial biogenesis to drive intratumoral T-cell metabolic insufficiency and dysfunction. Immunity 2016;45(2):374–88.59. Phan A.T., Doedens A.L., Palazon A. et al. Constitutive glycolytic metabolism supports CD8+ T-cell effector memory differentiation during viral infection. Immunity 2016;45(5):1024–7.Phan A.T., Doedens A.L., Palazon A. et al. Constitutive glycolytic metabolism supports CD8+ T-cell effector memory differentiation during viral infection. Immunity 2016;45(5):1024–7.60. Piret J.P., Mottet D., Raes M., Michiels C. Is HIF-1alpha a pro- or an anti-apoptotic protein? Biochem Pharmacol 2002;64(5–6):889–92.Piret J.P., Mottet D., Raes M., Michiels C. Is HIF-1alpha a pro- or an anti-apoptotic protein? Biochem Pharmacol 2002;64(5–6):889–92.61. Makino Y., Nakamura H., Ikeda E. et al. Hypoxia-inducible factor regulates survival of antigen receptor-driven T-cells. J Immunol 2003;171(12): 6534–40.Makino Y., Nakamura H., Ikeda E. et al. Hypoxia-inducible factor regulates survival of antigen receptor-driven T-cells. J Immunol 2003;171(12): 6534–40.62. Kerkar S.P., Restifo N.P. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res 2012;72(13):3125–30.Kerkar S.P., Restifo N.P. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res 2012;72(13):3125–30.63. Zhao E., Maj T., Kryczek I. et al. Cancer mediates effector T-cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol 2016;17(1):95–103.Zhao E., Maj T., Kryczek I. et al. Cancer mediates effector T-cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol 2016;17(1):95–103.64. Cui W., Liu Y., Weinstein J.S. et al. An interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation of memory CD8+ T-cells. Immunity 2011;35(5):792–805.Cui W., Liu Y., Weinstein J.S. et al. An interleukin-21-interleukin-10-STAT3 pathway is critical for functional maturation of memory CD8+ T-cells. Immunity 2011;35(5):792–805.65. Sukumar M., Kishton R.J., Restifo N.P. Metabolic reprograming of anti-tumor immunity. Curr Opin Immunol 2017;46:14–22.Sukumar M., Kishton R.J., Restifo N.P. Metabolic reprograming of anti-tumor immunity. Curr Opin Immunol 2017;46:14–22.